CJC-1295
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) consisting of a 29-amino-acid GHRH backbone, a modified GRF(1-29) analogue, with modifications designed to improve stability and prolong biological activity. Originally developed as a long-acting alternative to native GHRH, CJC-1295 incorporates amino acid substitutions that confer resistance to dipeptidyl peptidase-4 (DPP-4) degradation, extending its half-life from minutes to days.
Researchers have studied whether it may stimulate sustained endogenous growth hormone (GH) and insulin-like growth factor-1 (IGF-1) secretion. Its pharmacokinetic profile may allow less frequent dosing than other growth hormone secretagogues. Human outcome data remain limited, and CJC-1295 is not FDA approved.


Overview
CJC-1295 is reported to have greater stability than native GHRH because its amino acid modifications remove DPP-4 cleavage sites while preserving GHRH receptor binding affinity. The peptide exists in two forms: CJC-1295 with Drug Affinity Complex (DAC), which has an extended half-life, and CJC-1295 without DAC, which may produce more physiological pulsatile release patterns. The compound is metabolized primarily through peptidase enzymes and eliminated via renal excretion.

Chemical structure & Properties
- Molecular Formula: C165H269N47O46
- Molecular Weight: 3,647.28 Da
- Sequence: Modified GRF(1-29) with Lys substitution and maleimido-propionyl-Lys attachment
- Half-life: 6-8 days (with DAC), 30 minutes (without DAC)
- Stability: Enhanced resistance to DPP-4 degradation through amino acid modifications
Mechanism of Action
CJC-1295 exerts its therapeutic effects through multiple interconnected molecular pathways:
Areas Investigated in
the Research Literature

Current Clinical Evidence
Safety Profile and Considerations
Regulatory Status and Legal Considerations
Regulatory information current as of 28 August 2026. This is a summary, not legal or medical advice, and status can change.
FDA Status
- Classification: Investigational peptide - not approved for therapeutic use
- Approval Status: No FDA approval for human clinical applications
- Research Use: Limited to approved clinical trials and research protocols
- Regulatory Position:CJC-1295 is not on the FDA's active Category 2 list. It appears in the nominated-but-withdrawn section of the FDA's bulk drug substances page, meaning the nomination was withdrawn rather than acted on. Withdrawal does not authorize compounding: CJC-1295 is not on the FDA's 503A bulk drug substances list, so no lawful compounding pathway currently exists. It is not approved for therapeutic use.
WADA Status
- Classification: Prohibited under S2: Peptide Hormones, Growth Factors
- Athletic Use: Banned in competitive sports and athletic competitions
- Testing: Detectable through specialized anti-doping analysis methods
- Enforcement: Subject to sporting sanctions and competition disqualification
Legal Availability
- Commercial Status: Not legally available as prescription medication
- Market Presence: Available through research chemical suppliers and compounding pharmacies
- Quality Control: Limited regulatory oversight for purity, potency, and authenticity
- Clinical Use: Restricted to research institutions and experimental protocols

Conclusion
What the evidence supports
CJC-1295 is a long-acting growth-hormone-releasing hormone analog that has been studied in small, short-term human trials reporting sustained increases in growth hormone and IGF-1 levels. Outcome data is limited to those small studies, dosing has not been standardized, and there is no long-term safety data. CJC-1295 is not FDA approved for any therapeutic use and is not on the FDA's 503A bulk drug substances list, so no lawful compounding pathway currently exists; it is also prohibited under WADA. This page summarizes the published research and nothing further.
CJC-1295 SCIENTIFIC
DATA SUMMARY
About this library
This library is published for education. It summarizes published research on compounds studied in this field. Many have no approved medical use, and several cannot lawfully be compounded in the United States. The presence of a page here does not mean Paragon offers that compound. Nothing on these pages is an offer to treat.
This page is general education about a compound studied in this field. Nothing here is medical advice, a recommendation, or an offer to prescribe or supply. A page appearing in this library does not mean Paragon Sports Medicine offers that compound.
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. CJC-1295 is not approved by the FDA for human therapeutic use. Patients should consult with qualified healthcare providers before considering any peptide therapy.
Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Many peptides described here are not FDA approved for the uses discussed, and some cannot lawfully be compounded in the United States. Nothing on this page is medical advice or a recommendation for any individual. Whether any therapy is appropriate depends on your history, your laboratory results, and a clinical evaluation. Individual results vary. This page is published for education. Use of this site does not create a physician-patient relationship.